Ozempic Costs $100/Month on One Part D Plan and $310/Month on Another: Your 2026 GLP-1 Drug Cost Breakdown Before March 31
Ozempic Costs $100/Month on One Part D Plan and $310/Month on Another: Your 2026 GLP-1 Drug Cost Breakdown Before March 31
You're managing Type 2 diabetes and your doctor has you on Ozempic (semaglutide 1mg weekly). You signed up for a Part D plan last fall — picked something that looked reasonable — and now you're getting a bill that doesn't match what you expected. Or maybe you're looking at plans right now, wondering why the same drug has five different prices in the same ZIP code.
Here's what most people don't know: on three Part D plans available in a typical metro ZIP code right now, the same monthly supply of Ozempic costs $100, $235, or $310 — depending entirely on which plan you're enrolled in and how that plan categorizes the drug. By the end of the year, that gap compounds to as much as a $1,004 difference in total out-of-pocket cost. And if you enrolled in a Medicare Advantage plan that isn't covering your GLP-1 the way you expected, your window to fix that is closing March 31, 2026.
Let me walk you through the actual math.
First, a Critical Distinction Medicare Doesn't Explain Clearly
GLP-1 drugs (semaglutide, tirzepatide, liraglutide) are used for two distinct purposes — and Medicare treats them completely differently:
For Type 2 diabetes: Ozempic (semaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide) are covered by Medicare Part D because they have an FDA-indicated use to treat a chronic condition. Your plan must have them on formulary or grant an exception.
For weight loss only: Wegovy (semaglutide) and Zepbound (tirzepatide) are the same active molecules, but they're FDA-approved specifically for obesity. Medicare Part D is prohibited by federal statute from covering weight-loss drugs, full stop. Some Medicare Advantage plans have begun offering anti-obesity medication coverage as a supplemental benefit, but it's far from universal, and the benefit structure varies enormously by plan.
If your doctor prescribed Ozempic for diabetes and it's also helping you lose weight — that's fine, it's covered. If you're specifically prescribed Wegovy for obesity management, you are almost certainly paying out of pocket unless your MA plan has explicitly added it as a covered benefit for 2026. KFF Health News covered the clinical nuances well, noting that GLP-1s for weight loss work best when combined with lifestyle changes — which matters even more when you're managing those costs yourself.
This post focuses on the Part D-covered scenario: Ozempic or Mounjaro prescribed for Type 2 diabetes.
What "Formulary Tier" Actually Means (Without the Jargon)
A formulary is simply a plan's list of covered drugs, organized into pricing tiers. Think of it like a hotel pricing structure — the same chain charges different rates for the same room depending on how they've categorized it.
For specialty drugs like Ozempic:
- Tier 3 (Preferred Brand or Preferred Specialty): Lower cost-sharing, sometimes a fixed copay
- Tier 4 (Non-Preferred Brand or Standard Specialty): Higher coinsurance, typically 25–33%
- Tier 5 (Non-Preferred Specialty): Highest coinsurance, typically 25–33% on a higher base, sometimes after a deductible
The same drug, the same pharmacy, the same ZIP code — just different plans. That's what drives the price gap.
The Worked Math: Ozempic Across Three Real Plan Structures
Let's use Ozempic 1mg weekly (a standard diabetes dose), with a negotiated plan cost of $940/month — a realistic figure given typical Part D plan pricing for this drug. I'll model three plan structures that reflect actual designs you'll find on Medicare Plan Finder.
2026 Part D baseline parameters (per CMS):
- Standard deductible: up to $590
- Out-of-pocket cap (TrOOP): $2,000 — once you hit this, you pay $0 for the rest of the year
- Catastrophic phase: $0 cost-sharing
Plan A — Low Premium, Tier 5 Non-Preferred Specialty (33% Coinsurance, $590 Deductible)
| Month | Event | Your Cost | Running TrOOP |
|---|---|---|---|
| January | Pay deductible first | $590.00 | $590.00 |
| January (cont.) | 33% of remaining $350 | $115.50 | $705.50 |
| February | 33% of $940 | $310.20 | $1,015.70 |
| March | 33% of $940 | $310.20 | $1,325.90 |
| April | 33% of $940 | $310.20 | $1,636.10 |
| May | 33% of $940 | $310.20 | $1,946.30 |
| June | Hit $2,000 cap | $53.70 | $2,000.00 |
| July–December | Catastrophic phase | $0 | — |
Total drug OOP: $2,000 | Annual premium ($18/mo): $216 | Total annual cost: $2,216
Plan B — Higher Premium, Tier 4 Preferred Specialty (25% Coinsurance, $590 Deductible)
| Month | Event | Your Cost | Running TrOOP |
|---|---|---|---|
| January | Pay deductible first | $590.00 | $590.00 |
| January (cont.) | 25% of remaining $350 | $87.50 | $677.50 |
| February | 25% of $940 | $235.00 | $912.50 |
| March | 25% of $940 | $235.00 | $1,147.50 |
| April | 25% of $940 | $235.00 | $1,382.50 |
| May | 25% of $940 | $235.00 | $1,617.50 |
| June | 25% of $940 | $235.00 | $1,852.50 |
| July | Hit $2,000 cap | $147.50 | $2,000.00 |
| August–December | Catastrophic phase | $0 | — |
Total drug OOP: $2,000 | Annual premium ($52/mo): $624 | Total annual cost: $2,624
Plan C — Mid Premium, Preferred Specialty Fixed Copay ($0 Deductible for This Tier, $100/Month Copay)
| Month | Cost |
|---|---|
| January–December | $100.00/month |
| Annual drug costs | $1,200.00 |
| Never hits $2,000 cap | — |
Total drug OOP: $1,200 | Annual premium ($35/mo): $420 | Total annual cost: $1,620
Side-by-Side Summary
| Plan | Monthly Premium | Copay Structure | Annual Drug OOP | Annual Premium | Total Annual Cost |
|---|---|---|---|---|---|
| Plan A | $18 | 33%, $590 deductible | $2,000 | $216 | $2,216 |
| Plan B | $52 | 25%, $590 deductible | $2,000 | $624 | $2,624 |
| Plan C | $35 | $100 fixed, $0 deductible | $1,200 | $420 | $1,620 |
Plan C saves you $596 over Plan A and $1,004 over Plan B — despite having a higher premium than Plan A.
This is the counterintuitive reality of Part D math: a fixed low copay with no deductible can beat a percentage-based plan even when it has a higher monthly premium. If you never hit the $2,000 cap because your fixed copay keeps you below it, you win.
This kind of plan-by-plan analysis is exactly what Pelandri was built to run — so you're not guessing which structure wins for your specific drug list.
The Prior Authorization Trap
Here's what the plan comparison tables don't show you: most Part D plans require prior authorization (PA) for Ozempic and Mounjaro. That means your pharmacist can't just fill the prescription — the plan needs documentation that you have a Type 2 diabetes diagnosis, that you've tried (and possibly failed) other medications, and that the drug is being used for an approved indication.
If you're switching plans and the PA from your old plan doesn't automatically transfer, you could face a gap in coverage while the new plan processes paperwork. This is especially relevant right now, during the Medicare Advantage Open Enrollment Period.
Step therapy is another layer: some plans require you to try metformin, a sulfonylurea, or another diabetes drug before they'll cover a GLP-1. If you're already stable on Ozempic, you can request a step therapy exception — but it takes time and a doctor's letter. Don't wait until your prescription runs out to start that process.
As I've written about in the Eliquis and Lisinopril comparison post, prior authorization and tier exception requests are under-used tools that can dramatically reduce what you pay — but only if you know to ask for them.
The March 31 Deadline: What It Means If You're in Medicare Advantage
The Medicare Advantage Open Enrollment Period (MA OEP) runs January 1 through March 31 every year. According to the Medicare Rights Center, this window allows you to make one coverage change if you're currently enrolled in a Medicare Advantage plan:
- Switch from one MA plan to another MA plan
- Disenroll from your MA plan and return to Original Medicare (adding a standalone Part D plan and, if desired, a Medigap supplement)
Changes made now take effect the first of the following month. If you switch in the last week of March, your new coverage starts May 1.
Why does this matter for GLP-1 users specifically? A few scenarios:
- Your MA plan's formulary changed for 2026 and now requires step therapy or PA that's more burdensome than you expected
- You're paying a high specialty tier coinsurance through your MA plan's integrated drug coverage and found a standalone Part D plan with a better structure
- You need Wegovy or Zepbound for obesity and your current MA plan doesn't cover it, but another plan in your area has added it as a supplemental benefit for 2026
The deadline is real. If you're unhappy with how your current plan covers your GLP-1 medications and you're in a Medicare Advantage plan, March 31 is your last chance to act until Open Enrollment in the fall. You can model the difference between your current plan and alternatives at Pelandri — entering your actual drugs, dose, and ZIP code to see the full-year cost comparison.
The $2,000 Cap Changed the Math — But Didn't Eliminate the Comparison
For high-cost specialty drugs like GLP-1s, the Inflation Reduction Act's $2,000 out-of-pocket cap (now fully in effect for 2026) is genuinely protective. As the Medicare Rights Center noted in its recent review of the ACA's 16-year legacy, drug cost protections layered onto Medicare over the past decade have meaningfully reduced financial exposure for beneficiaries on expensive medications.
But the cap isn't a reason to stop comparing plans. As the table above shows, the plan with a fixed $100 copay kept total drug costs at $1,200 — $800 below the cap — meaning the cap never even applied. That's a better outcome than reaching the cap through a high-coinsurance plan, even though both paths technically offer "$2,000 maximum exposure."
The cap protects you from catastrophic runaway costs. It doesn't make all plans equivalent. For drugs like Eliquis, the math is similar — the $2,000 ceiling matters, but the path you take to get there (or whether you get there at all) determines your actual bill.
What to Do Right Now
If you take Ozempic, Mounjaro, or any other GLP-1 for diabetes, here's your action list before March 31:
-
Check your current plan's tier placement for your GLP-1. Log into your plan's website or call the member services number on your card. Ask: "What tier is Ozempic on, and is a prior authorization required?"
-
Run a full-year cost comparison using your actual drug list, doses, and preferred pharmacy. The Medicare Plan Finder at medicare.gov does this — but it requires you to manually check each plan. Pelandri pulls this across all available plans in your ZIP code so you can see the ranked total cost in one view.
-
If you're in Medicare Advantage, confirm whether your plan covers anti-obesity GLP-1s (Wegovy/Zepbound) as a supplemental benefit, and whether switching plans before March 31 would get you better coverage.
-
Ask your doctor to check if a tier exception is warranted. If your GLP-1 is on Tier 5 but a clinically equivalent drug is on Tier 3, a formulary exception request — supported by your physician — can move your cost-sharing down. It's not guaranteed, but it's worth a letter.
The math on GLP-1 drugs is unforgiving if you're on the wrong plan. A $1,000 swing is real money — and the only way to know which side of it you're on is to run the numbers for your specific situation before the clock runs out.
Sources
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health — KFF Medicare
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment — KFF Medicare
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions — KFF Medicare
- Sixteen Years of the Affordable Care Act — Medicare Rights Center
- The Annual Deadline to Make Certain Medicare Advantage Changes Is Fast Approaching — Medicare Rights Center